Q1 2023
Released Aug 5, 2022, before the open
10-Q filed Aug 5, 2022, 36 days after period end · 0001764013-22-000085
Q1 2023 · 10-Q
Revenue—
Net Income-$40.37M-$40.37M N/M vs Q1 2022N/M vs Q4 2022
EPS Diluted-$0.35-$0.35 N/M vs Q1 2022no prior Q4 2022 on file
Operating Cash Flow-$65,819,000N/M
Free Cash Flowderived-$65,861,000N/M
What the release said
The release
Same quarter
| Metric | Q1 2023 | Q1 2022 | Q1 2019 | Q1 2018 |
|---|---|---|---|---|
| Net Income | -$40.37M | -$30.47M | -$20.06M | -$4.37M |
| EPS Diluted | -$0.35 | -$0.31 | -$0.52 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR